首页> 外国专利> Method for treating Multiple Sclerosis which involves the use of laquinimod and glatiramer acetate and kit comprising Pharmaceutical compositions containing both compounds independently.

Method for treating Multiple Sclerosis which involves the use of laquinimod and glatiramer acetate and kit comprising Pharmaceutical compositions containing both compounds independently.

机译:一种治疗多发性硬化症的方法,该方法包括使用拉喹莫德和醋酸格拉替雷和包含独立地包含两种化合物的药物组合物的试剂盒。

摘要

This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
机译:本发明提供了一种治疗患有多发性硬化症或表现出临床分离的综合症的患者的方法,该方法包括给予该患者拉喹莫德作为醋酸格拉替雷的附加疗法或与醋酸格拉替雷组合。本发明还提供了包含拉喹莫德和醋酸格拉替雷的包装和药物组合物,用于治疗患有多发性硬化症或表现出临床分离的综合症的患者。本发明还提供了拉喹莫德,其用作附加疗法或与醋酸格拉替雷组合用于治疗患有多发性硬化症或临床上孤立的综合症的患者。本发明进一步提供了拉喹莫德和醋酸格拉替雷在制备用于治疗患有多发性硬化症或表现出临床分离的综合征的患者的组合中的用途。

著录项

  • 公开/公告号CL2014000209A1

    专利类型

  • 公开/公告日2014-08-22

    原文格式PDF

  • 申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD.;

    申请/专利号CL20140000209

  • 发明设计人 TARCIC NORA;GILGUN YOSSI;

    申请日2014-01-28

  • 分类号A61K31/47;A61K38/02;A61P25/00;

  • 国家 CL

  • 入库时间 2022-08-21 15:58:28

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号